130 related articles for article (PubMed ID: 21502798)
41. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
Cozzi R; Montini M; Attanasio R; Albizzi M; Lasio G; Lodrini S; Doneda P; Cortesi L; Pagani G
J Clin Endocrinol Metab; 2006 Apr; 91(4):1397-403. PubMed ID: 16449332
[TBL] [Abstract][Full Text] [Related]
42. The efficacy of octreotide LAR (long acting release) treatment in patients with somatotropinoma, and mixed pituitary tumours.
Waśko R; Bolko P; Owecki M; Jaskuła M; Sowiński J
Pharm World Sci; 2004 Dec; 26(6):324-7. PubMed ID: 15683101
[TBL] [Abstract][Full Text] [Related]
43. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study.
Colao A; Zgliczyński W; Komorowski J; Kos-Kudła B; Tabarin A; Kerlan V; Minuto FM; Scaroni C; Bolanowski M
Endokrynol Pol; 2019; 70(4):305-312. PubMed ID: 31274183
[TBL] [Abstract][Full Text] [Related]
45. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
46. Pituitary adenoma associated with gigantism and hyperprolactinemia.
Alikasifoglu A; Kandemir N; Akalan N; Yordam N
Pediatr Neurosurg; 2001 Dec; 35(6):325-8. PubMed ID: 11786701
[TBL] [Abstract][Full Text] [Related]
47. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
48. [Octreotide in the treatment of thyrotropin-secreting pituitary adenomas].
Podoba J; Hnilica P; Makaiová I; Kovácová S; Rybár M; Gecík K; Belan V; Steno J
Vnitr Lek; 1997 Sep; 43(9):607-10. PubMed ID: 9750471
[TBL] [Abstract][Full Text] [Related]
49. A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. French Multicenter Octreotide Study Group.
Warnet A; Harris AG; Renard E; Martin D; James-Deidier A; Chaumet-Riffaud P
Neurosurgery; 1997 Oct; 41(4):786-95; discussion 796-7. PubMed ID: 9316039
[TBL] [Abstract][Full Text] [Related]
50. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide.
Ezzat S; Kontogeorgos G; Redelmeier DA; Horvath E; Harris AG; Kovacs K
Eur J Endocrinol; 1995 Dec; 133(6):686-90. PubMed ID: 8548053
[TBL] [Abstract][Full Text] [Related]
51. Octreotide.
Lamberts SW; van der Lely AJ; de Herder WW; Hofland LJ
N Engl J Med; 1996 Jan; 334(4):246-54. PubMed ID: 8532003
[No Abstract] [Full Text] [Related]
52. Thyrotropin secreting pituitary adenoma associated with hypopituitarism and diabetes insipidus in an adolescent boy.
Phillip M; Hershkovitz E; Kornmehl P; Cohen A; Leiberman E
J Pediatr Endocrinol Metab; 1995; 8(1):47-50. PubMed ID: 7584697
[TBL] [Abstract][Full Text] [Related]
53. [Monosymptomatic hyperthyroidism and TSH-producing adenoma: successful therapy with octreotide].
Mayinger B; Axelos D; Pavel M; Hahn EG; Hensen J
Dtsch Med Wochenschr; 1999 Jan; 124(4):73-8. PubMed ID: 10071603
[TBL] [Abstract][Full Text] [Related]
54. A patient with acromegaly who showed remarkable improvement of hyperglycemia after treatment with octreotide.
Hirose T; Kuroda T; Otsuki M; Takagi M; Yamamoto H; Motomura T; Kurebayashi S; Miyashita Y; Koga M; Arita N; Hayakawa T; Kishimoto T; Kasayama S
Intern Med; 1997 May; 36(5):345-50. PubMed ID: 9213172
[TBL] [Abstract][Full Text] [Related]
55. Successful pregnancy in an acromegalic women treated with octreotide.
Takeuchi K; Funakoshi T; Oomori S; Maruo T
Obstet Gynecol; 1999 May; 93(5 Pt 2):848. PubMed ID: 10912424
[No Abstract] [Full Text] [Related]
56. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
57. Response of ACTH to octreotide in a probable corticotropic adenoma associated with Addison's disease.
Suárez-Llanos JP; Fernández-Fernández E; Checa MR; Jara-Albarrán A
Neuro Endocrinol Lett; 2007 Oct; 28(5):549-53. PubMed ID: 17984930
[TBL] [Abstract][Full Text] [Related]
58. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study.
Shen M; Shou X; Wang Y; Zhang Z; Wu J; Mao Y; Li S; Zhao Y
Endocr J; 2010; 57(12):1035-44. PubMed ID: 21099129
[TBL] [Abstract][Full Text] [Related]
59. Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995).
Warnet A; Lajeunie E; Gelbert F; Duet M; Chanson P; Cophignon J; Harris AG
Acta Endocrinol (Copenh); 1991 Apr; 124(4):487-91. PubMed ID: 2031445
[TBL] [Abstract][Full Text] [Related]
60. Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study.
Kristof RA; Stoffel-Wagner B; Klingmüller D; Schramm J
Acta Neurochir (Wien); 1999; 141(4):399-405. PubMed ID: 10352750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
